EDAP TMS S.A. Reports $17.8 Million Revenue in Q1 2026, Driven by HIFU Division Growth

EDAP TMS S.A. reported a total revenue of $17.8 million for the first quarter of 2026, marking a 24.8% increase from $14.3 million in the same period of 2025. The growth was primarily driven by a significant rise in the company's High Intensity Focused Ultrasound (HIFU) division, which saw revenues increase by 78.3% to $11.6 million, up from $6.5 million year-over-year. This increase was attributed to higher sales of medical devices, particularly the Focal One robotic HIFU systems, which sold 11 units in the first quarter of 2026 compared to 6 units in the prior year. Despite the revenue growth, the company reported a net loss of $9.1 million, an increase from a loss of $7.4 million in the same quarter of the previous year.

The company's operational expenses rose to $15.5 million, up from $12.3 million in the first quarter of 2025, largely due to increased selling and marketing expenses, which reached $7.1 million. General and administrative expenses also surged by 58.5% to $5.8 million, driven by costs associated with the company's transition to a U.S. domestic filer status. The gross profit margin improved to 45.7% from 42.0%, reflecting the higher margins associated with HIFU sales and better absorption of fixed costs due to increased production volumes.

In terms of strategic developments, EDAP TMS has shifted its focus towards enhancing its HIFU activities while de-emphasizing its non-HIFU Distribution and ESWL divisions. This strategic pivot has resulted in a decline in revenues from the ESWL division, which fell by 15.8% to $1.5 million, and the Distribution division, which decreased by 21.2% to $4.7 million. The company is also actively exploring additional financing options to support its operations and growth initiatives, as it anticipates needing substantial capital to meet cash flow requirements in the future.

As of March 31, 2026, EDAP TMS had $15.0 million in cash and cash equivalents, a decrease of $5.4 million from the end of 2025. The company drew on Tranche B of its credit facility with the European Investment Bank in April 2026, which is expected to provide sufficient funds to support operations for at least the next twelve months. However, management has indicated that additional financing may be necessary to sustain operations and achieve profitability, and they are considering various alternatives, including cost-cutting measures and restructuring opportunities.

Looking ahead, EDAP TMS remains focused on expanding its HIFU business and improving its product offerings. The company is committed to driving sales growth in the U.S. and other markets while continuing to manage its operational costs amid ongoing inflationary pressures. The outlook remains cautious, as the company acknowledges the potential need for further capital to support its strategic initiatives and navigate the challenges of the current economic environment.